PRFX Stock Increases Over 60% Pre-Market: Details You Should Know

By Amit Chowdhry ● July 22, 2021
  • The stock price of PainReform Ltd (NASDAQ: PRFX) increased by over 60% pre-market. These are some details you should know.

The stock price of PainReform Ltd (NASDAQ: PRFX) increased by over 60% pre-market. There is not any company-specific news or notable SEC filings from the company. 

Retail investors on social media have been citing the low float as an opportunity for driving up momentum. And there is speculation that the company is getting closer to making an announcement about their Phase 3 clinical trials of PRF-110. 

PRF-110 — the company’s lead product — is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. And PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The company’s proprietary extended-release drug-delivery system is designed for providing an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.